tetano
Editor, Senior Moderator
Mol Ther. 2013 Feb;21(2):485-492. doi: 10.1038/mt.2012.246. Epub 2016 Dec 6.
[h=1]Virus-like Particles Containing Multiple M2 Extracellular Domains Confer Improved Cross-protection Against Various Subtypes of Influenza Virus.[/h] Kim MC[SUP]1[/SUP], Song JM[SUP]2[/SUP], Eunju O[SUP]3[/SUP], Kwon YM[SUP]3[/SUP], Lee YJ[SUP]4[/SUP], Compans RW[SUP]5[/SUP], Kang SM[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The extracellular domain of M2 (M2e), a small ion channel membrane protein, is well conserved among different human influenza A virus strains. To improve the protective efficacy of M2e vaccines, we genetically engineered a tandem repeat of M2e epitope sequences (M2e5x) of human, swine, and avian origin influenza A viruses, which was expressed in a membrane-anchored form and incorporated in virus-like particles (VLPs). The M2e5x protein with the transmembrane domain of hemagglutinin (HA) was effectively incorporated into VLPs at a several 100-fold higher level than that on influenza virions. Intramuscular immunization with M2e5x VLP vaccines was highly effective in inducing M2e-specific antibodies reactive to different influenza viruses, mucosal and systemic immune responses, and cross-protection regardless of influenza virus subtypes in the absence of adjuvant. Importantly, immune sera were found to be sufficient for conferring protection in naive mice, which was long-lived and cross-protective. Thus, molecular designing and presenting M2e immunogens on VLPs provide a promising platform for developing universal influenza vaccines without using adjuvants.
Copyright ? 2013 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
PMID: 28160844 DOI: 10.1038/mt.2012.246
[PubMed - in process]
[h=1]Virus-like Particles Containing Multiple M2 Extracellular Domains Confer Improved Cross-protection Against Various Subtypes of Influenza Virus.[/h] Kim MC[SUP]1[/SUP], Song JM[SUP]2[/SUP], Eunju O[SUP]3[/SUP], Kwon YM[SUP]3[/SUP], Lee YJ[SUP]4[/SUP], Compans RW[SUP]5[/SUP], Kang SM[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The extracellular domain of M2 (M2e), a small ion channel membrane protein, is well conserved among different human influenza A virus strains. To improve the protective efficacy of M2e vaccines, we genetically engineered a tandem repeat of M2e epitope sequences (M2e5x) of human, swine, and avian origin influenza A viruses, which was expressed in a membrane-anchored form and incorporated in virus-like particles (VLPs). The M2e5x protein with the transmembrane domain of hemagglutinin (HA) was effectively incorporated into VLPs at a several 100-fold higher level than that on influenza virions. Intramuscular immunization with M2e5x VLP vaccines was highly effective in inducing M2e-specific antibodies reactive to different influenza viruses, mucosal and systemic immune responses, and cross-protection regardless of influenza virus subtypes in the absence of adjuvant. Importantly, immune sera were found to be sufficient for conferring protection in naive mice, which was long-lived and cross-protective. Thus, molecular designing and presenting M2e immunogens on VLPs provide a promising platform for developing universal influenza vaccines without using adjuvants.
Copyright ? 2013 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
PMID: 28160844 DOI: 10.1038/mt.2012.246
[PubMed - in process]